Rapid Relief from Severe Depression Achieved with New 5-MeO-DMT Nasal Spray in Clinical Trials

Derived from Frog Venom: A Promising Nasal Spray Offers New Hope for Depression

According to НВ — Техно: Clinical trials have revealed that a novel nasal spray containing synthetic 5-MeO-DMT, sourced from the venom of the Incilius alvarius toad, can quickly ease symptoms of severe depression. The study involved 193 participants suffering from moderate to severe depression, many of whom had not responded to conventional antidepressants, highlighting the spray’s potential as an alternative treatment option.

Participants were recruited from clinics across Australia, Europe, and the United States, all having previously tried between two and five standard antidepressants without meaningful improvement. The nasal spray delivers mebufotenin benzoate in doses of 0.3 mg, 8 mg, or 12 mg. Results showed that the 8 mg and 12 mg doses produced sustained improvements lasting eight weeks or longer. Unlike many psychedelics, the drug’s psychoactive effects last about an hour, allowing patients to leave the clinic within two hours of administration.

Key Findings from the Study

On average, patients experienced around a 30% improvement in symptoms. However, expert Chittaranjan Andrade noted that remission rates were lower compared to treatments like ketamine or electroconvulsive therapy (

“remission rates were lower than those seen with ketamine or ECT”

). Side effects reported were generally mild to moderate, including headache, nausea, and temporary nasal discomfort. The 8 mg dose was identified as optimal, offering the best balance between safety and therapeutic benefit.

The research was funded by biotech firm AtaiBeckley and published in the Journal of the American Medical Association (JAMA). It’s important to note that patients with suicidal tendencies were excluded from the trial, and further study is needed to assess the long-term effectiveness of this monotherapy. While these findings open new avenues in depression treatment, cautious interpretation and additional research are essential.

This innovative treatment approach could represent a significant advancement for individuals unresponsive to traditional antidepressants. Nonetheless, more extensive research is required to determine the long-term safety and effectiveness of the spray, as well as its impact across diverse forms of depression. The positive outcomes of this study may encourage further scientific exploration within psychiatry and psychopharmacology.

As researchers continue to explore innovative treatments for mental health disorders, findings from a recent study suggest that antidepressants may also enhance outcomes for cancer patients undergoing immunotherapy. This connection highlights the potential for integrated treatment approaches that address both mental and physical health challenges simultaneously.